文献速递基础与转化研究新药、器械与细胞基因治疗研发

p53突变对三氧化二砷的拯救效力差异由内在突变特性预先决定

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.
PubMed 文献 · Sci Transl Med · 2023-04-05

研究评估了800种常见p53突变体被三氧化二砷(ATO)拯救的效力,发现拯救效力主要由突变残基的溶剂可及性和突变蛋白的温度敏感性决定。390种突变体被不同程度拯救,其中33种1型突变体拯救量接近野生型;在PDX小鼠试验和临床试验中,ATO优先抑制携带1型和2a型突变体的肿瘤,并首次在患者中实现突变p53再激活。

要点

  • 800种p53突变体中390种可被ATO不同程度拯救,33种1型突变体拯救量接近野生型。
  • 拯救效力主要由突变残基溶剂可及性和突变蛋白温度敏感性决定。
  • PDX小鼠试验和临床试验中ATO优先抑制携带1型和2a型突变体的肿瘤。

核心结论

  • p53突变对ATO的拯救效力由突变内在特性预先决定,并提出基于个体突变等位基因而非突变类型的p53靶向策略。

研究设计与样本

  • 评估800种常见p53突变体被ATO拯救的效力,检测指标包括反式激活活性、细胞生长抑制和小鼠肿瘤抑制活性,并在PDX小鼠试验、临床试验及47株源自10种癌症类型的细胞系中验证。

主要发现

  • 390种p53突变体被不同程度拯救,分为1型、2a型和2b型;33种1型突变体拯救量接近野生型。
  • 在PDX小鼠试验中,ATO优先抑制携带1型和2a型突变体的肿瘤生长。
  • 在一项ATO临床试验中,首次在携带1型V272M突变体的患者中实现突变p53再激活。
  • 在源自10种癌症类型的47株细胞系中,ATO优先且有效地拯救1型和2a型突变体。

临床怎么用

  • 作者提出基于个体突变等位基因而非突变类型的p53靶向策略,并提供p53突变可成药性资源网站www.rescuep53.net。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumor suppressor p53 is inactivated by thousands of heterogeneous mutations in cancer, but their individual druggability remains largely elusive. Here, we evaluated 800 common p53 mutants for their rescue potencies by the representative generic rescue compound arsenic trioxide (ATO) in terms of transactivation activity, cell growth inhibition, and mouse tumor-suppressive activities. The rescue potencies were mainly determined by the solvent accessibility of the mutated residue, a key factor determining whether a mutation is a structural one, and the temperature sensitivity, the ability to reassemble the wild-type DNA binding surface at a low temperature, of the mutant protein. A total of 390 p53 mutants were rescued to varying degrees and thus were termed as type 1, type 2a, and type 2b mutations, depending on the degree to which they were rescued. The 33 type 1 mutations were rescued to amounts comparable to the wild type. In PDX mouse trials, ATO preferentially inhibited growth of tumors harboring type 1 and type 2a mutants. In an ATO clinical trial, we report the first-in-human mutant p53 reactivation in a patient harboring the type 1 V272M mutant. In 47 cell lines derived from 10 cancer types, ATO preferentially and effectively rescued type 1 and type 2a mutants, supporting the broad applicability of ATO in rescuing mutant p53. Our study provides the scientific and clinical communities with a resource of the druggabilities of numerous p53 mutations (www.rescuep53.net) and proposes a conceptual p53-targeting strategy based on individual mutant alleles rather than mutation type.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Song H, Wu J, Tang Y, et al. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci Transl Med. 2023. PMID: 37018419. doi:10.1126/scitranslmed.abn9155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。